Biosimilar key opinion leader, Dr. Paul Rhyne, Chief Scientific Officer and Vice President of Bioanalytical Operations at Biologics Development Services (BDS), provides an overview of the current state of biosimilars and their global impact. Rhyne brings his over 20 years of experience in developing biologics to the topic of biosimilars and discusses how cost and patient access play a big role in this new field of research.

Listen Here

Download

Duration: 13:38
File size: 13.2 MB
Recommended browsers: Google Chrome and Mozilla Firefox.

 

For more information about biosimilars purification and applications, visit our resource page.

Interested in biosimilar development?

Sign up to get resources and learn about our biosimilar development workflow.

Thank you for requesting more information.

Please look out for an email from Bio‑Rad. From purification to characterization, we can guide you through better biosimilar development.

Humira is a trademark of AbbVie Biotechnology Ltd.

 

Previous post

Preamplification and How it Can Be Used to Maximize qPCR Data Generation from Limited Samples

Next post

Bio-Plex® Multiplex Immunoassay Technology Overview and Setting Up to Run an Assay